Adatanserin

Adatanserin (WY-50,324, SEB-324) is a mixed 5-HT1A receptor partial agonist and 5-HT2A and 5-HT2C receptor antagonist. It was under development by Wyeth as an antidepressant but appears to have been abandoned. Adantaserin also has neuroprotective effects against ischemia-induced glutamatergic excitotoxicity.